(UroToday.com) Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. mCRPC has well-known molecular heterogeneity, with approximately 25% of patients having defects in deoxyribonucleic acid (DNA) repair genes, most of which are homologous recombination repair mutations (HRRm), such as BRCA1, BRCA2, and ATM).1,2 There is a lack of individualized treatment options for patients harboring HRR gene alterations when compared to the general mCRPC population.